Developer docs
API playgroundTry for free, no card

Search company profiles

NeoSome Life Sciences

Full company profile

uuid000epqr

Namestring
NeoSome Life Sciences
Legal namestring
NeoSome Life Sciences
Websiteurl
neosomels.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

NeoSome Life Sciences is a preclinical contract research organization (CRO) founded in 2014 and headquartered in Billerica, Massachusetts, with a satellite mailing address in Lexington. The company provides both in-vivo and in-vitro drug discovery support services to pharmaceutical and biotechnology companies, and to a lesser extent academic institutions, operating from a 30,000 sq. ft. AAALAC-, OLAW-, and USDA-compliant facility that includes a BSL-2 suite, clean rooms, surgical facilities, and a dedicated vivarium. Its service portfolio spans five core areas — infectious disease, oncology, pharmacology, in vitro services, and additional disease models (metabolic, inflammation, behavioral) — with technical capabilities including IVIS imaging, Meso Scale Discovery (MSD) multiplexing up to 10 analytes, 14-color flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, and hematology.

The business model is a professional services / project-based contract research model. NeoSome does not publish pricing; engagements are scoped through direct consultation with study directors and scientific account managers, with revenue tied to study design complexity, animal models used, and assay requirements. Customer segments are horizontally distributed across large pharma, emerging biotech, and academia, with go-to-market executed through a consultative direct sales motion supplemented by LinkedIn presence, blog content marketing, email newsletters, and conference participation (e.g., RESI).

Operationally, NeoSome has invested in scale (new 2022 facility), breadth (expanded in-house in-vitro menu in 2023), and compliance (AAALAC accreditation in October 2024). The company is privately held with no disclosed funding rounds, no named customers, no revenue disclosure, and no disclosed ownership or investor base, limiting external visibility into financial trajectory.

Short descriptiontext

NeoSome Life Sciences is a preclinical contract research organization providing in-vivo and in-vitro drug discovery services — including infectious disease, oncology, pharmacology, and bioanalytical assays — to pharmaceutical and biotechnology companies from its AAALAC-accredited facility in Billerica, Massachusetts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBillerica, United States
HQ citystring
Billerica
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical contract research, drug discovery services, animal disease models, in vivo efficacy studies, in vitro bioanalytical assays
Industry4 codes
PRIMARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Project-based contract research services where NeoSome conducts preclinical studies on behalf of pharmaceutical and biotech clients. Services span multiple stages of drug discovery including proof of concept, in-vitro assays, and drug efficacy evaluations in animal models of human disease. Revenue is generated through individual study contracts with pricing based on study design complexity, animal models used, and assay requirements.

neosomels.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NeoSome Life Sciences is a contract research organization that conducts preclinical in-vivo and in-vitro studies on behalf of pharmaceutical and biotechnology clients. Services span the drug discovery pipeline and include infectious disease models, oncology models, pharmacology and PK studies, in-vitro bioanalytical assays (MSD, flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, hematology), and specialized animal disease models in metabolic, inflammation, and behavioral research. Each engagement is custom-designed with the company's study directors and scientific staff guiding animal model selection, protocol design, execution, data analysis, and interpretation.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

NeoSome Life Sciences is a full-service contract research organization (CRO) providing preclinical drug discovery support through multiple service platforms. The company operates a unified service offering organized around five core research areas: Infectious Disease Research Services, Oncology Research Services, Pharmacology Services, In Vitro Services Platform, and Additional Research Models. The In Vitro Services Platform encompasses sub-services including MSD (Meso Scale Discovery), Flow Cytometry, Western Blot, ELISA, Clinical Chemistry & Hematology, and Cell-Based Assays. These services are designed to work together across drug discovery stages from proof of concept through in vivo efficacy evaluation, with the company supporting both standard assay panels and custom assay development.

Product and service11 records
1Infectious Disease Research Services
CategoryIn-vivo / in-vitro infectious disease research
Description

Anti-infective agent evaluation combining in-vitro assays (MICs, MBCs, PAEs, Time Kill curves, Checkerboard assays, susceptibility testing) with in-vivo models (Mouse Protection Test, rodent pulmonary models, kidney infection models, C. difficile models, neutropenic models, fungal infection models) for pharmaceutical and biotech clients developing anti-infective drugs.

2Oncology Research Services
CategoryIn-vivo oncology research
Description

Broad portfolio of oncology models covering all research phases, from cell toxicity assays to efficacy models and pharmacodynamic assessments, using IVIS imaging technology for orthotopic tumor imaging, surgical implantation visualization, and longitudinal tumor burden tracking. Designed for pharma and biotech oncology programs.

3Pharmacology Services
CategoryIn-vivo pharmacology / PK studies
Description

Pharmacology testing including tolerability assessments, formulation evaluations, and single- and multi-dose pharmacokinetic studies administered via IV, PO, SC, IP, IM, and ID routes across rodent species, supporting preclinical drug development programs.

4In Vitro Services Platform
CategoryIn-vitro bioanalytical assays
Description

Unified in-house in-vitro services platform providing high sensitivity and specificity using standard and custom panels with low sample volumes, supporting drug discovery programs through bioanalytical assays (MSD, flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, hematology).

5Meso Scale Discovery (MSD) Service
CategoryIn-vitro protein biomarker assay
Description

Electrochemiluminescence-based protein detection offering higher sensitivity than traditional ELISA, with multiplexing capability up to 10 analytes from a single small sample, run on the MESO QuickPlex SQ 120MM platform for pharma and biotech biomarker work.

6Flow Cytometry Service
CategoryIn-vitro immunophenotyping / cell profiling
Description

Multi-parameter flow cytometry supporting up to 14 colors for immunophenotyping and cell profiling, with applications in immunotherapy including CAR-T, CAR-NK, bi-specific T Cell engagers, checkpoint inhibitors, vaccines, and immune modulators.

7Western Blot Service
CategoryIn-vitro protein analysis
Description

SDS-PAGE and Western blot analysis for protein target isolation, detection, and quantitation in test samples for pharma and biotech drug discovery programs.

8ELISA Service
CategoryIn-vitro protein biomarker assay
Description

Kit-based or custom ELISA assays for detection and quantitation of protein biomarkers, using a spectrophotometer imaging system capable of both visible and chemiluminescent signals.

9Clinical Chemistry & Hematology Service
CategoryIn-vitro clinical pathology
Description

In-house clinical chemistry analyzer with full test panels (liver, kidney, endocrine, metabolic, toxicology) paired with a HemaVet hematology analyzer for complete blood counts across multiple species, using fresh sample protocols that require smaller sample volumes for reproducible results.

10Cell-Based Assays Service
CategoryIn-vitro cell biology assay
Description

Drug-cell interaction assays including cytotoxicity assays, MTT assays, IC50 determinations, and clonogenic assays with customizable parameters to support pharma and biotech discovery research.

11Additional Research Models
CategorySpecialized animal disease models
Description

Specialized animal disease models including Metabolic Disease Models (DIO, STZ-induced diabetes, Zucker Fatty Rat, db/db, ob/ob), Inflammation Models (LPS, AIA, EAE, DTH, CIA, CAIA), and Behavioral Models (Forced Swim Test, Elevated Plus Maze, Modified Irwin Battery, PanLab Smart Track), with real-time animal tracking and customizable analysis.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeoSome Life Sciences

Preclinical Contract Research Servicesneosomels.com

NeoSome Life Sciences is a preclinical contract research organization providing in-vivo and in-vitro drug discovery services — including infectious disease, oncology, pharmacology, and bioanalytical assays — to pharmaceutical and biotechnology companies from its AAALAC-accredited facility in Billerica, Massachusetts.

What NeoSome Life Sciences does

NeoSome Life Sciences is a preclinical contract research organization (CRO) founded in 2014 and headquartered in Billerica, Massachusetts, with a satellite mailing address in Lexington. The company provides both in-vivo and in-vitro drug discovery support services to pharmaceutical and biotechnology companies, and to a lesser extent academic institutions, operating from a 30,000 sq. ft. AAALAC-, OLAW-, and USDA-compliant facility that includes a BSL-2 suite, clean rooms, surgical facilities, and a dedicated vivarium. Its service portfolio spans five core areas — infectious disease, oncology, pharmacology, in vitro services, and additional disease models (metabolic, inflammation, behavioral) — with technical capabilities including IVIS imaging, Meso Scale Discovery (MSD) multiplexing up to 10 analytes, 14-color flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, and hematology.

The business model is a professional services / project-based contract research model. NeoSome does not publish pricing; engagements are scoped through direct consultation with study directors and scientific account managers, with revenue tied to study design complexity, animal models used, and assay requirements. Customer segments are horizontally distributed across large pharma, emerging biotech, and academia, with go-to-market executed through a consultative direct sales motion supplemented by LinkedIn presence, blog content marketing, email newsletters, and conference participation (e.g., RESI).

Operationally, NeoSome has invested in scale (new 2022 facility), breadth (expanded in-house in-vitro menu in 2023), and compliance (AAALAC accreditation in October 2024). The company is privately held with no disclosed funding rounds, no named customers, no revenue disclosure, and no disclosed ownership or investor base, limiting external visibility into financial trajectory.

NeoSome Life Sciences firmographics

Firmographics
Name
NeoSome Life Sciences
Legal name
NeoSome Life Sciences
Website
https://neosomels.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
NeoSome Life Sciences is a preclinical contract research organization providing in-vivo and in-vitro drug discovery services — including infectious disease, oncology, pharmacology, and bioanalytical assays — to pharmaceutical and biotechnology companies from its AAALAC-accredited facility in Billerica, Massachusetts.
Ownership category
akta.pro rank

NeoSome Life Sciences industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Preclinical contract research
  • Drug discovery services
  • Animal disease models
  • In vivo efficacy studies
  • In vitro bioanalytical assays

Where NeoSome Life Sciences is headquartered

Location

Headquarters

HQ city
Billerica
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeoSome Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Research Services: Project-based contract research services where NeoSome conducts preclinical studies on behalf of pharmaceutical and biotech clients. Services span multiple stages of drug discovery including proof of concept, in-vitro assays, and drug efficacy evaluations in animal models of human disease. Revenue is generated through individual study contracts with pricing based on study design complexity, animal models used, and assay requirements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

NeoSome Life Sciences product offering

Product offering

Core offering

NeoSome Life Sciences is a contract research organization that conducts preclinical in-vivo and in-vitro studies on behalf of pharmaceutical and biotechnology clients. Services span the drug discovery pipeline and include infectious disease models, oncology models, pharmacology and PK studies, in-vitro bioanalytical assays (MSD, flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, hematology), and specialized animal disease models in metabolic, inflammation, and behavioral research. Each engagement is custom-designed with the company's study directors and scientific staff guiding animal model selection, protocol design, execution, data analysis, and interpretation.

Product overview

NeoSome Life Sciences is a full-service contract research organization (CRO) providing preclinical drug discovery support through multiple service platforms. The company operates a unified service offering organized around five core research areas: Infectious Disease Research Services, Oncology Research Services, Pharmacology Services, In Vitro Services Platform, and Additional Research Models. The In Vitro Services Platform encompasses sub-services including MSD (Meso Scale Discovery), Flow Cytometry, Western Blot, ELISA, Clinical Chemistry & Hematology, and Cell-Based Assays. These services are designed to work together across drug discovery stages from proof of concept through in vivo efficacy evaluation, with the company supporting both standard assay panels and custom assay development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Infectious Disease Research Services Anti-infective agent evaluation combining in-vitro assays (MICs, MBCs, PAEs, Time Kill curves, Checkerboard assays, susceptibility testing) with in-vivo models (Mouse Protection Test, rodent pulmonary models, kidney infection models, C. difficile models, neutropenic models, fungal infection models) for pharmaceutical and biotech clients developing anti-infective drugs.
  • Oncology Research Services Broad portfolio of oncology models covering all research phases, from cell toxicity assays to efficacy models and pharmacodynamic assessments, using IVIS imaging technology for orthotopic tumor imaging, surgical implantation visualization, and longitudinal tumor burden tracking. Designed for pharma and biotech oncology programs.
  • Pharmacology Services Pharmacology testing including tolerability assessments, formulation evaluations, and single- and multi-dose pharmacokinetic studies administered via IV, PO, SC, IP, IM, and ID routes across rodent species, supporting preclinical drug development programs.
  • In Vitro Services Platform Unified in-house in-vitro services platform providing high sensitivity and specificity using standard and custom panels with low sample volumes, supporting drug discovery programs through bioanalytical assays (MSD, flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, hematology).
  • Meso Scale Discovery (MSD) Service Electrochemiluminescence-based protein detection offering higher sensitivity than traditional ELISA, with multiplexing capability up to 10 analytes from a single small sample, run on the MESO QuickPlex SQ 120MM platform for pharma and biotech biomarker work.
  • Flow Cytometry Service Multi-parameter flow cytometry supporting up to 14 colors for immunophenotyping and cell profiling, with applications in immunotherapy including CAR-T, CAR-NK, bi-specific T Cell engagers, checkpoint inhibitors, vaccines, and immune modulators.
  • Western Blot Service SDS-PAGE and Western blot analysis for protein target isolation, detection, and quantitation in test samples for pharma and biotech drug discovery programs.
  • ELISA Service Kit-based or custom ELISA assays for detection and quantitation of protein biomarkers, using a spectrophotometer imaging system capable of both visible and chemiluminescent signals.
  • Clinical Chemistry & Hematology Service In-house clinical chemistry analyzer with full test panels (liver, kidney, endocrine, metabolic, toxicology) paired with a HemaVet hematology analyzer for complete blood counts across multiple species, using fresh sample protocols that require smaller sample volumes for reproducible results.
  • Cell-Based Assays Service Drug-cell interaction assays including cytotoxicity assays, MTT assays, IC50 determinations, and clonogenic assays with customizable parameters to support pharma and biotech discovery research.
  • Additional Research Models Specialized animal disease models including Metabolic Disease Models (DIO, STZ-induced diabetes, Zucker Fatty Rat, db/db, ob/ob), Inflammation Models (LPS, AIA, EAE, DTH, CIA, CAIA), and Behavioral Models (Forced Swim Test, Elevated Plus Maze, Modified Irwin Battery, PanLab Smart Track), with real-time animal tracking and customizable analysis.

Companies that use NeoSome Life Sciences

Customer profile

Segments3 records

Ideal customer profiles3 records

NeoSome Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NeoSome Life Sciences partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

NeoSome Life Sciences competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

NeoSome Life Sciences social profiles

Digital presence

NeoSome Life Sciences compliance and trust

Trust signal

Compliance1 record

NeoSome Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeoSome Life Sciences leadership team

Management profile

Number of profiles

NeoSome Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeoSome Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoSome Life Sciences

What does NeoSome Life Sciences do?

NeoSome Life Sciences is a contract research organization that conducts preclinical in-vivo and in-vitro studies on behalf of pharmaceutical and biotechnology clients. Services span the drug discovery pipeline and include infectious disease models, oncology models, pharmacology and PK studies, in-vitro bioanalytical assays (MSD, flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, hematology), and specialized animal disease models in metabolic, inflammation, and behavioral research. Each engagement is custom-designed with the company's study directors and scientific staff guiding animal model selection, protocol design, execution, data analysis, and interpretation.

Is NeoSome Life Sciences a public or private company?

NeoSome Life Sciences is a private company. It is classified as unknown and is currently operating.

When was NeoSome Life Sciences founded?

NeoSome Life Sciences was founded in 2014. It employs 11 to 50 people.

Where is NeoSome Life Sciences based?

NeoSome Life Sciences is headquartered in Billerica, United States, in the North America region.

How does NeoSome Life Sciences make money?

One revenue line is on record: contract Research Services.

Does NeoSome Life Sciences have an API?

No public API is recorded for NeoSome Life Sciences.

What industry is NeoSome Life Sciences in?

NeoSome Life Sciences's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAFAA, In Vivo Pharmacology (Efficacy/PD Models), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales